Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
Executive Summary
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
You may also be interested in...
Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?
FDA's finalized guidance on off-label reprints contains small modifications that appear to satisfy free speech critics of the draft version. But it does not offer sufficient change to mollify congressional critics who believe the document is too permissive
Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?
FDA's finalized guidance on off-label reprints contains small modifications that appear to satisfy free speech critics of the draft version. But it does not offer sufficient change to mollify congressional critics who believe the document is too permissive
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach